Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ILOPERIDONE vs ABILIFY MYCITE KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iloperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors; also moderate affinity for D3, D4, 5-HT6, 5-HT7, and α1-adrenergic receptors; low affinity for H1, 5-HT1A, and α2-adrenergic receptors; no affinity for M1 muscarinic receptors.
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
Acute treatment of schizophrenia in adults
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
1-2 mg orally twice daily; target dose 6-12 mg/day; maximum 12 mg/day
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
Terminal elimination half-life 18 hours in extensive CYP2D6 metabolizers, 33 hours in poor metabolizers; clinical context: steady-state reached in ~5-7 days.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Primarily metabolized by CYP3A4 and CYP2D6 to two major metabolites (P88 and P95); also a minor substrate of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2E1.
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; approximately 7% excreted unchanged in urine and 18% in feces; total renal elimination of metabolites ~25%, fecal ~60%.
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
~95% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
Vd/F ~20 L/kg (oral); large distribution indicates extensive tissue binding.
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
Oral bioavailability is approximately 96% relative to oral solution; food does not significantly affect absorption.
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
GFR 30-59 m L/min: reduce dose by 50%; GFR 15-29 m L/min: reduce by 75%; GFR <15 m L/min: not recommended
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: contraindicated
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Not established; safety and efficacy not evaluated in patients <18 years
Not approved for patients <18 years; safety and effectiveness not established.
Initiate at 1 mg twice daily; increase slowly; monitor for orthostatic hypotension and anticholinergic effects
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Iloperidone is not approved for the treatment of patients with dementia-related psychosis.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis,QT interval prolongation (particularly with concomitant use of drugs that prolong QT or in patients with risk factors),Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Orthostatic hypotension (particularly during initial dose titration),Seizures,Leukopenia, neutropenia, and agranulocytosis,Body temperature regulation impairment,Dysphagia,Cognitive and motor impairment
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
Known hypersensitivity to iloperidone or any component of the formulation
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Grapefruit juice may inhibit CYP3A4 metabolism, increasing iloperidone concentrations; avoid concurrent use. High-fat meals may slightly reduce absorption; take consistency.
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
First trimester: Limited human data; animal studies show increased fetal resorption and developmental delays at doses similar to human exposure. Second and third trimesters: May cause extrapyramidal symptoms and/or withdrawal symptoms in neonates (e.g., agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
Iloperidone is excreted into human milk. M/P ratio: unknown. Use caution; consider benefits of breastfeeding vs. risk of infant exposure. Monitor infant for sedation, poor feeding, extrapyramidal symptoms.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
No specific dose adjustment guidelines exist for pregnancy. Due to increased plasma volume and renal clearance during pregnancy, consider therapeutic drug monitoring to maintain efficacy. Lower doses may be needed if adverse effects occur; use lowest effective dose.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
Iloperidone is an atypical antipsychotic with a low propensity for extrapyramidal symptoms but significant QTc prolongation risk; obtain baseline ECG and monitor electrolytes. Titrate slowly to mitigate orthostatic hypotension due to alpha-1 blockade. Dosing adjustments required in CYP2D6 poor metabolizers (reduce dose by 50%). Avoid concomitant use with QT-prolonging drugs or CYP3A4/2D6 inhibitors/inducers.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
Do not drive or operate machinery until you know how iloperidone affects you, as it may cause dizziness, drowsiness, or blurred vision.,Rise slowly from sitting or lying positions to prevent falls due to low blood pressure.,Report any fast, pounding, or irregular heartbeat, especially with lightheadedness or fainting.,Avoid alcohol and grapefruit juice as they may increase side effects or drug levels.,If you experience muscle stiffness, fever, confusion, or sweating, seek emergency help immediately, as these may be signs of neuroleptic malignant syndrome.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
"Iloperidone, an atypical antipsychotic, prolongs the QT interval by blocking cardiac potassium channels (hERG), while Methsuximide, a succinimide anticonvulsant, may also prolong the QT interval via similar mechanisms. Co-administration can lead to additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias. This is particularly dangerous in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"The interaction between iloperidone and aprepitant results from iloperidone's moderate inhibition of CYP3A4, the primary enzyme responsible for aprepitant metabolism. This inhibition can lead to increased aprepitant plasma concentrations, potentially enhancing its antiemetic effects and risk of adverse events such as hiccups, constipation, and headache. Clinical significance is greater during the 3-day aprepitant regimen for chemotherapy-induced nausea and vomiting, as elevated levels may prolong its therapeutic and side effect profile."
"Concomitant administration of propoxycaine, an ester-type local anesthetic, and iloperidone, an atypical antipsychotic, may increase the risk of QT interval prolongation and torsade de pointes due to additive effects on cardiac repolarization. Propoxycaine can also elevate catecholamine levels, potentially enhancing iloperidone's effects on blood pressure and heart rate. These interactions could manifest as palpitations, syncope, or life-threatening arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ILOPERIDONE vs ABILIFY MYCITE KIT, answered by our medical review team.
ILOPERIDONE is a Atypical Antipsychotic that works by Iloperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors; also moderate affinity for D3, D4, 5-HT6, 5-HT7, and α1-adrenergic receptors; low affinity for H1, 5-HT1A, and α2-adrenergic receptors; no affinity for M1 muscarinic receptors.. ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ILOPERIDONE and ABILIFY MYCITE KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ILOPERIDONE is: 1-2 mg orally twice daily; target dose 6-12 mg/day; maximum 12 mg/day. The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ILOPERIDONE and ABILIFY MYCITE KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ILOPERIDONE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and developmental delays at doses similar to human exposure. Second and third trimesters: May ca. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.